A phase i trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors

Investigational New Drugs

Volumn 33, Issue 6, 2015, Pages 1225-1231

  McRee, Autumn J ^a   Sanoff, Hanna K ^a   Carlson, Cheryl ^a   Ivanova, Anastasia ^a   O'Neil, Bert H ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 fluorouracil; BKM120; Gastrointestinal malignancies; Oxaliplatin; PI3K pathway

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BUPARLISIB; CISPLATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; OXALIPLATIN; TRIACYLGLYCEROL LIPASE; AMINOPYRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; MORPHOLINE DERIVATIVE; NVP-BKM120; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CAUSE OF DEATH; CLINICAL ARTICLE; COHORT ANALYSIS; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FATIGUE; FEMALE; FEVER; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; LEUKOPENIA; LIVER CELL CARCINOMA; LYMPHOCYTOPENIA; MALE; MORNING DOSAGE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE COURSE; MIDDLE AGED; NEOPLASMS; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; AMINOPYRIDINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LEUKOPENIA; MALE; MIDDLE AGED; MORPHOLINES; NAUSEA; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PHOSPHATIDYLINOSITOL 3-KINASE;

EID: 84947427465     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-015-0298-3     Document Type: Article

References (17)

1. Brown KK, Toker A (2015) The phosphoinositide 3-kinase pathway and therapy resistance in cancer. F1000Prime Rep 7:13
2. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2(7):489-501
3. Cai X et al. (2015) Synergistic inhibition of colon carcinoma cell growth by Hedgehog-Gli1 inhibitor arsenic trioxide and phosphoinositide 3-kinase inhibitor LY294002. Onco Targets Ther 8:877-883
4. Cheng HB et al. (2015) Longikaurin E induces apoptosis of pancreatic cancer cells via modulation of the p38 and PI3K/AKT pathways by ROS. Naunyn Schmiedeberg's Arch Pharmacol 388(6):623-634
5. Simioni C et al. (2015) The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells. Oncotarget 6:17147-17160
6. Zheng YB et al. (2015) Paeoniflorin inhibits human gastric carcinoma cell proliferation through up-regulation of microRNA-124 and suppression of PI3K/Akt and STAT3 signaling. World J Gastroenterol 21(23):7197-7207
7. Horiguchi H et al. (2014) Angiopoietin-like protein 2 renders colorectal cancer cells resistant to chemotherapy by activating spleen tyrosine kinase-phosphoinositide 3-kinase-dependent anti-apoptotic signaling. Cancer Sci 105(12):1550-1559
8. Li B et al. (2014) Suppression of esophageal tumor growth and chemoresistance by directly targeting the PI3K/AKT pathway. Oncotarget 5(22):11576-11587
9. Ng SSW et al. (2000) Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 60(19):5451-5455
10. Bendell JC et al. (2012) Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 30(3):282-290
11. Hyman DM et al. (2015) Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. Cancer Chemother Pharmacol 75(4):747-755
12. Mayer IA et al. (2014) Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 32(12):1202-1209
13. Zambrano CC, Schuler MH, Machiels J-PH, Hess D, Paz-Ares L, Awada A, von Moos R, Steeghs N, Ahnert JR, De Mesmaeker P, Richly H, Herremans C, Joerger M, Jaime JC, Alsina M, Baffert F, Demanse D, Duval V, Morozov A, Dirix L (2014) Phase lb study of buparlisib (BKM120) plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC). J Clin Oncol 32(5s):abstract 627
14. Goldberg RM et al. (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22(1):23-30
15. Tournigand C et al. (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22(2):229-237
16. Feng JP et al. (2013) Secondary diabetes associated with 5-fluorouracil-based chemotherapy regimens in non-diabetic patients with colorectal cancer: results from a single-centre cohort study. Color Dis 15(1):27-33
17. Feng JP et al. (2010) Impact of 5-fluorouracil on glucose metabolism and pancreatic pathology in rats. Zhonghua Wei Chang Wai Ke Za Zhi 13(12):935-938